Centene Corp.

Centene Corp.

CNC

$66.78

Updated: 03/11/2026, 18:05:51

Market Cap
$33.06B
Sector
Healthcare
Industry
Medical - Healthcare Plans
Country
US

No historical data available

Company Profile

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

USD
NYSE
CEO: Sarah McGinty London
Employees: 61,100
https://www.centene.com
Asset Summaries
Latest generated summaries for CNC

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
CNC-10-k-fy2025.html3.0 MBtext/htmlENFiled 17/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 61 KPI observations

Revenue

$174.6B

FY 2025 · Reported

Net income

$-6.7B

FY 2025 · Reported

Gross margin

98.5%

FY 2025 · Calculated

Free cash flow

$4.3B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$0.5B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Segment product families

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Nation's largest managed care company focused on underserved populations; mission to transform the health of communities served

98%
Source evidence
“As the nation's largest managed care company focused on underserved populations, Centene is committed to helping people live healthier lives.”

Four operating segments (2025)

Medicaid, Medicare, Commercial and Other segments operated during 2025

98%
Source evidence
“During 2025, we operated in four segments: Medicaid, Medicare, Commercial and Other.”

Government payor dependence and state concentration

Centene derives a significant portion of premium revenues from government payors across a number of states; decreases in premium revenue or profitability in any one state could materially adversely affect the business.

92%
Source evidence
“the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers)”

Segment product families

Full product portfolio across Medicaid, Medicare, Commercial and Other segments

95%
Source evidence
“Medicaid - includes the Temporary Assistance for Needy Families (TANF) program; Medicaid Expansion programs; the Aged, Blind or Disabled (ABD) program”

Segment revenues FY2025 vs FY2024

Medicaid $110,434M; Medicare $37,210M; Commercial $42,003M; Other $5,130M; Total $194,777M (2025, $M)

100%
Source evidence
“Medicaid$110,434 $101,417 9 % Medicare37,210 23,032 62 % Commercial42,003 33,702 25 % Other5,130 4,920 4 % Consolidated Total$194,777 $163,071 19 %”

Gross margin by segment FY2025 vs FY2024

Consolidated gross margin $14,209M in 2025, down 17%; Commercial down $2.6B

100%
Source evidence
“Medicaid$5,690 $6,246 (9)% Medicare2,983 2,595 15 % Commercial5,101 7,663 (33)% Other435 565 (23)% Consolidated Total$14,209 $17,069 (17)%”

External revenue mix by segment FY2025

Medicaid 57%, Commercial 21%, Medicare 19%, Other 3% of total external revenues (FY2025)

97%
Source evidence
“our Medicaid, Commercial, Medicare and Other segments accounted for 57%, 21%, 19% and 3%, respectively, of our total external revenues”

Positioning and strategy

Competitive position drivers

Key competitive drivers include benefit plan breadth/pricing, provider network size/quality, service quality, ratings, financial stability, and local market presence

90%
Source evidence
“Key drivers of our competitive position include: •Breadth and pricing of benefit plans •Size and quality of provider networks”

Medicaid cost pressure drivers

Higher behavioral health, home health and high-cost drug costs; redeterminations lowered membership

100%
Source evidence
“Gross margin decreased due to higher medical costs driven primarily by behavioral health, home health and high-cost drugs, partially offset by rate and revenue increases.”

Commercial Marketplace growth and margin decline

26% Marketplace membership growth; margin hit by lower risk adjustment and higher Marketplace medical costs

100%
Source evidence
“Total revenues increased 25% in the year ended December 31, 2025, compared to the corresponding period in 2024 primarily driven by 26% membership growth in the Marketplace business, partially offset by lower estimated risk adjustment revenue.”

Medicare growth from PDP

PDP premium yield and membership growth; IRA-driven PDP program changes

100%
Source evidence
“Total revenues increased 62% in the year ended December 31, 2025, compared to the corresponding period in 2024, primarily driven by increased PDP premium yield and membership, partially offset by lower Medicare Advantage membership.”

Expiration of Enhanced APTCs threatens Marketplace membership and morbidity

Expiration of Enhanced APTCs and additional program integrity initiatives for Marketplace products could reduce membership or raise risk-pool morbidity.

93%
Source evidence
“including due to the expiration of the Enhanced Advance Premium Tax Credits (APTCs) and additional program integrity initiatives for Marketplace products”

Magellan Health divestiture agreement

Definitive agreement signed December 2025 to divest the remaining Magellan Health businesses

95%
Source evidence
“We signed a definitive agreement to divest the remaining Magellan Health businesses in December 2025.”

CMS market growth projections

CMS estimates Medicaid spending growing ~7%/yr to $1.5T by 2031 and Medicare ~8%/yr to $1.9T by 2031; >40% of Medicare spend still fee-for-service

93%
Source evidence
“CMS estimates Medicaid spending will grow at an average annual rate of 7% to $1.5 trillion by 2031”

Market leadership positions

Largest Medicaid and Marketplace insurer and largest stand-alone PDP provider; 12.5M Medicaid members in 30 states; 1.0M MA members in 32 states (Wellcare brand)

96%
Source evidence
“we are the nation's largest Medicaid and Marketplace insurer, as well as the largest stand-alone PDP provider”

Risks, financing, and outlook

Pharmaceutical cost exposure

Increases in pharmaceutical costs, including new high-cost specialty drugs, could materially increase medical costs and harm results of operations.

93%
Source evidence
“Increases in our pharmaceutical costs could have a material adverse effect on the level of our medical costs and our results of operations”

Other segment margin decline

Circle Health divestiture and TRICARE contract expiration reduced Other segment margin

90%
Source evidence
“driven by the Circle Health divestiture in the first quarter of 2024 along with the expiration of the TRICARE Managed Care Support Contract in December 2024.”

Senior notes and credit facilities

$15.5B senior notes; $2.0B term loan drawn; undrawn $4.0B revolver (matures March 2030); notes mature Dec 2027–Aug 2031

100%
Source evidence
“we had an aggregate principal amount of $15.5 billion of senior notes issued and outstanding. The indentures governing our various maturities of senior notes contain limited restrictive covenants.”

2026 capex and liquidity outlook

Expect ~$800M 2026 capex; liquidity sufficient for at least 12 months

100%
Source evidence
“we expect to spend approximately $800 million in capital expenditures primarily associated with system enhancements and computer hardware and software.”

2026 Marketplace refiled rates approved in vast majority of states

We have received approvals in the vast majority of states for our 2026 refiled Marketplace rates reflecting the increased medical expenses we experienced in 2025 and adjusted our benefit design and strategy.

95%
Source evidence
“While we have received approvals in the vast majority of states for our 2026 refiled Marketplace rates reflecting the increased medical expenses we experienced in 2025 and adjusted our benefit design and strategy, these actions may not be sufficient to maintain or increase the profitability of these products”

New York Essentials Plan-5 termination

New York intends to terminate its Essentials Plan-5 (state-subsidized coverage for 200%-250% FPL) by July 1, 2026

92%
Source evidence
“New York intends to terminate its Essentials Plan-5, which provided state-subsidized healthcare for individuals from 200% to 250% of the Federal Poverty Level (FPL) by July 1, 2026”

Two Medicare Advantage contracts terminated for plan year 2025

Two of our Medicare Advantage contracts received notice of termination for plan year 2025.

95%
Source evidence
“For example, two of our Medicare Advantage contracts received notice of termination for plan year 2025.”

Goodwill impairment reduced equity

Q3 2025 goodwill impairment reduced stockholders' equity

90%
Source evidence
“The debt-to-capital ratio increase was driven by the goodwill impairment recorded in the third quarter of 2025, which reduced total stockholders' equity.”

OBBBA (July 2025) Medicaid impacts

One Big Beautiful Bill Act may reduce Medicaid Expansion eligibility, increase morbidity from 2027, and reduce federal Medicaid funding via provider tax/state directed payment changes from 2028

94%
Source evidence
“The One Big Beautiful Bill Act (OBBBA), passed in July 2025, includes requirements that may reduce the number of members eligible for state Medicaid Expansion programs”

2025 Medicaid medical cost trend

During 2025, Medicaid membership had higher than expected medical costs, including unanticipated increased costs in behavioral health, home health and high-cost drugs.

98%
Source evidence
“during 2025, our Medicaid membership had higher than expected medical costs, including due to unanticipated increased costs in behavioral health, home health and high-cost drugs”

2025 Marketplace risk adjustment revenue shortfall

Late in Q2 2025, independent actuarial data showed materially higher implied aggregate morbidity of the Marketplace membership, causing a significant reduction of expected net risk adjustment revenue for 2025.

98%
Source evidence
“late in the second quarter of 2025, data from an independent actuarial firm suggested a materially higher implied aggregate morbidity of the Marketplace membership as a whole than anticipated, resulting in a significant reduction of our expected net risk adjustment revenue for 2025”

Government program participation and procurement risk

States or other governmental entities may carve out services, not allow continued participation in government programs, or Centene may fail to win procurements, materially and adversely affecting results of operations, financial condition and cash flows.

95%
Source evidence
“or they may not allow us to continue to participate in their government programs or we may fail to win procurements to participate in such programs”

Star rating termination threshold

Our Medicare Advantage and PDP contracts may be terminated by CMS if our Medicare Advantage contracts receive Star ratings of below 3.0 stars for three consecutive years.

95%
Source evidence
“our Medicare Advantage and PDP contracts may be terminated by CMS if our Medicare Advantage contracts receive Star ratings of below 3.0 stars for three consecutive years”

Pharmacy benefit services regulatory risk

PBM services face regulatory risks including rules on ownership of pharmacies by insurance companies, rebates from pharmaceutical companies, formularies, and use of average wholesale prices.

95%
Source evidence
“including ownership of pharmacies by insurance companies, the receipt or disclosure of rebates from pharmaceutical companies, the development and use of formularies and the use of average wholesale prices”

Medicaid redetermination acuity risk

After the PHE expiration and Medicaid redeterminations, the Company continues to experience a higher HBR among remaining members due to acuity profile and eligibility gaps.

93%
Source evidence
“we have continued to experience a higher HBR related to the remaining members, due to the acuity profile of this membership, as well as the gaps in eligibility for certain members who have rejoined the Medicaid plans”

Rate-setting lag in Medicaid profitability

The delay between claims payments and receiving state rate adjustments when medical expense trend accelerates may reduce Medicaid plan profitability.

92%
Source evidence
“The delay in time between making claims payments and receiving rate adjustments when we experience an increased rate of change in medical expenses... may cause the profitability of our Medicaid plans to be reduced”

Third-party vendor information system cybersecurity exposure

Regulatory reviews include cybersecurity issues related to Centene's or its third-party vendors' information systems.

90%
Source evidence
“cybersecurity issues, including those related to our or our third-party vendors' information systems, HIPAA and other federal and state fraud, waste and abuse laws”

Drug pricing benchmark dependency

Contracts rely on third-party published pricing benchmarks; if these are no longer published or regulation requires other benchmarks, impacts may be materially adverse.

90%
Source evidence
“Contracts in the prescription drug industry generally use pricing metrics published by third parties as benchmarks to establish pricing for prescription drugs.”

Material exposure graph

State Medicaid agencies
Revenue Exposure

State Medicaid contracts, with Florida and New York each ~10%+ of Medicaid premium revenues, are core revenue sources

Relevance 92·Dependency 88·Confidence 93
Source evidence
“Our Medicaid contracts with the states of Florida and New York accounted for approximately 10% or more of our consolidated Medicaid premium revenues individually”
Marketplace (ACA) members
Demand Driver

26% Marketplace membership growth drove 25% Commercial revenue growth; but higher Marketplace medical costs and lower risk adjustment revenue cut Commercial gross margin by $2.6B.

Relevance 92·Dependency 85·Confidence 100
Source evidence
“primarily driven by 26% membership growth in the Marketplace business, partially offset by lower estimated risk adjustment revenue”
One Big Beautiful Bill Act (OBBBA)
Regulatory Exposure

OBBBA work requirements, redeterminations, cost sharing, and funding changes could shrink membership and raise morbidity largely from 2027

Relevance 92·Dependency 80·Confidence 93
Source evidence
“These changes could have the effect of increasing the overall morbidity of the Medicaid Expansion population largely beginning in 2027”
Enhanced Advance Premium Tax Credits expiration
Revenue Exposure

Expiration of Enhanced APTCs and program integrity initiatives can reduce Marketplace membership and raise risk-pool morbidity.

Relevance 92·Dependency 75·Confidence 93
Source evidence
“including due to the expiration of the Enhanced Advance Premium Tax Credits (APTCs) and additional program integrity initiatives for Marketplace products”
Government program funding
Demand Driver

Medicaid revenue growth driven by premium tax revenue and rate increases; Medicare PDP growth driven by IRA program changes; redeterminations reduced membership.

Relevance 90·Dependency 88·Confidence 90
Source evidence
“primarily driven by increased premium tax revenue and rate increases, partially offset by lower membership, primarily due to redeterminations”
State Medicaid programs
Revenue Exposure

Significant premium revenues come from state contracts; rate setting is controlled by state actuaries and rate adjustments may lag acuity.

Relevance 90·Dependency 85·Confidence 92
Source evidence
“As part of the Medicaid rate setting process, state actuaries determine actuarial soundness of rates based on historical data.”
Medical cost inflation
Cost Driver

Higher medical costs from behavioral health, home health and high-cost drugs reduced Medicaid gross margin by $556 million; increased Marketplace medical costs cut Commercial margin.

Relevance 90·Dependency 82·Confidence 100
Source evidence
“higher medical costs driven primarily by behavioral health, home health and high-cost drugs”
CMS Star ratings
Regulatory Exposure

Star ratings drive quality bonus and rebates and contracts can be terminated below 3.0 stars for three consecutive years.

Relevance 90·Dependency 80·Confidence 95
Source evidence
“Star ratings are subject to change annually by CMS... there can be no assurances that we will be successful in maintaining or improving our Star ratings in future years, which could negatively impact our quality bonus and rebates”
Federal government / CMS
Revenue Exposure

Medicare Advantage and PDP revenue depends on annual CMS bids and contract continuity; CMS can terminate contracts.

Relevance 90·Dependency 80·Confidence 92
Source evidence
“if we do not submit adequate bids in our existing markets or any expansion markets; if our existing contracts are modified or terminated”
Pharmaceutical costs
Cost Driver

Rising pharmaceutical costs, including new high-cost specialty drugs, directly increase medical costs and pressure HBR.

Relevance 88·Dependency 75·Confidence 93
Source evidence
“Increases in our pharmaceutical costs could have a material adverse effect on the level of our medical costs and our results of operations”
Healthcare regulation (federal and state)
Regulatory Exposure

Operations comprehensively regulated at local, state, federal levels; Star ratings and state contract awards shape competitive outcomes

Relevance 88·Dependency 75·Confidence 92
Source evidence
“Our operations are comprehensively regulated at the local, state and federal levels.”
Medicaid redeterminations
Demand Driver

Post-PHE redeterminations shifted membership acuity and eligibility gaps, raising HBR on remaining Medicaid members.

Relevance 88·Dependency 70·Confidence 93
Source evidence
“as a result of the expiration of the public health emergency (PHE) due to the COVID-19 pandemic, and the resulting Medicaid redeterminations process... we have continued to experience a higher HBR related to the remaining members”
CMS Medicare and Marketplace regulations
Regulatory Exposure

Compliance with CMS Medicare and Marketplace regulations, including risk adjustment, is a subject of compliance reviews and investigations that could adversely affect results.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“compliance with the CMS Medicare and Marketplace regulations, including risk adjustment, prior authorizations and broker compensation”
Centers for Medicare & Medicaid Services (CMS)
Revenue Exposure

Medicare segment revenues from CMS are significant; MA and PDP premiums come from CMS contracts

Relevance 85·Dependency 80·Confidence 92
Source evidence
“Revenues from CMS are significant to the segment.”
Government healthcare program funding
Demand Driver

Changes in state and federal funding for government-sponsored healthcare programs, including under new administrations, are a key risk.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“the amount and terms of state and federal funding for government-sponsored healthcare programs, including as a result of changes in U.S. presidential administrations or Congress”
Medicare Part D (PDP) members
Demand Driver

Increased PDP premium yield and membership, plus IRA program changes, drove Medicare revenues up 62% and gross margin up $388 million.

Relevance 85·Dependency 75·Confidence 100
Source evidence
“primarily driven by program changes in the PDP business as a result of the IRA along with premium yield and membership growth”
Government contract bidding competition
Competitive Exposure

Competes with MCOs, specialty providers and non-traditional entrants for state, county, federal and commercial contracts

Relevance 82·Dependency 75·Confidence 90
Source evidence
“We compete with MCOs, specialty providers and emerging non-traditional entrants to secure and retain state, county, federal, and commercial contracts.”
Medicaid redeterminations
Regulatory Exposure

Medicaid membership declined due to redeterminations, partially offsetting rate increases.

Relevance 80·Dependency 70·Confidence 100
Source evidence
“partially offset by lower membership, primarily due to redeterminations”
One Big Beautiful Bill Act (OBBBA)
Cost Driver

OBBBA-driven changes to healthcare regulations and eligibility affect utilization and cost prediction.

Relevance 80·Dependency 65·Confidence 88
Source evidence
“Changes in healthcare regulations and practices, including due to the OBBBA, the level of utilization of healthcare services, including due to eligibility changes”
Aging and dual-eligible population growth
Demand Driver

ABD beneficiaries are a growing share of Medicaid recipients and ~12 million dual-eligibles drive demand for D-SNP/LTSS products

Relevance 78·Dependency 70·Confidence 88
Source evidence
“According to CMS, there were approximately 12 million dual-eligible enrollees in 2025.”
Inflation Reduction Act (IRA)
Regulatory Exposure

Medicare PDP gross margin increase was primarily driven by program changes resulting from the IRA.

Relevance 78·Dependency 65·Confidence 100
Source evidence
“primarily driven by program changes in the PDP business as a result of the IRA”
Medicaid procurement protests
Legal Exposure

Protests and appeals related to Medicaid procurement awards are disclosed litigation/contingency exposures affecting government program participation.

Relevance 75·Dependency 60·Confidence 85
Source evidence
“and protests and appeals related to Medicaid procurement awards”
Interest rates
Cost Driver

Lower interest rates and lower average investment balances reduced investment and other income by $212 million in 2025.

Relevance 70·Dependency 55·Confidence 100
Source evidence
“The decrease was driven by lower interest rates and lower average investment balances during 2025”
False Claims Act
Legal Exposure

Compliance with the False Claims Act is among recurring federal and state reviews and investigations requiring management attention and potentially costly proceedings.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“compliance with the False Claims Act, the calculation of minimum MLR and rebates related thereto”
TRICARE beneficiaries
Revenue Exposure

Expiration of the TRICARE Managed Care Support Contract in December 2024 contributed to a $130 million decline in Other segment gross margin.

Relevance 55·Dependency 35·Confidence 90
Source evidence
“along with the expiration of the TRICARE Managed Care Support Contract in December 2024”
Full company information
Latest profile, trading, valuation, and identifier data stored for CNC.
Share price
$66.78
Market cap
$33.06B
Exchange
NYSE
Currency
USD
CEO
Sarah McGinty London
Employees
61,100
IPO date
13/12/2001
Beta
1.105
Last dividend
$0.00
Day range
$66.11 – $67.46
52-week range
$31.63 – $72.50
1-day performance
0.38%
1-year performance
111.13%
Current drawdown (1Y)
-7.89%
CIK
0001071739
CUSIP
15135B101
ISIN
US15135B1017
Created
07/12/2025, 03:22:40
Last update
03/11/2026, 18:05:51

Track Centene Corp. with an AI analyst

See which prediction-market events move CNC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to CNC from your Railway `news_articles` table.